We can’t show the full text here under this license.
Abstract
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is the most prevalent chronic liver disease globally.
- MASLD is associated with increased risk of cardiovascular disease, including myocardial infarction and ischemic stroke.
- Epidemiologic data show a consistent link between MASLD and adverse cardiovascular outcomes.
- Subclinical changes in vascular structure and function can occur before overt cardiovascular events.
- Glucagon-like-peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors may provide benefits for both liver and cardiovascular health.
- Recent trials indicate variability in the efficacy of treatments among different patient populations, especially in those with heart failure and cirrhosis.
- Non-invasive diagnostic tools are improving the accuracy of MASLD staging and risk assessment, although their implementation varies and cost-effectiveness for cardiovascular screening remains unclear.
Simplified